Katia Tonkin

9.0k total citations · 3 hit papers
86 papers, 6.5k citations indexed

About

Katia Tonkin is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Katia Tonkin has authored 86 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 22 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Katia Tonkin's work include Cancer Treatment and Pharmacology (17 papers), Bone health and treatments (15 papers) and Cancer Diagnosis and Treatment (11 papers). Katia Tonkin is often cited by papers focused on Cancer Treatment and Pharmacology (17 papers), Bone health and treatments (15 papers) and Cancer Diagnosis and Treatment (11 papers). Katia Tonkin collaborates with scholars based in Canada, United States and United Kingdom. Katia Tonkin's co-authors include John R. Mackey, Allan Lipton, Guenther G. Steger, Susie Jun, Jean-Jacques Body, Michelle Fan, Amit M. Oza, Alison Stopeck, Sheryl Koski and Ada Braun and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Katia Tonkin

86 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

2010 1.1k citations Alison Stopeck, Allan Lipton et al. Journal of Clinical Oncology profile →
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment

2009 856 citations Carla M. Prado, Katia Tonkin et al. profile →
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

2011 850 citations Karen A. Gelmon, Katia Tonkin et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Katia Tonkin

Since Specialization

Citations

This map shows the geographic impact of Katia Tonkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katia Tonkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katia Tonkin more than expected).

Fields of papers citing papers by Katia Tonkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katia Tonkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katia Tonkin. The network helps show where Katia Tonkin may publish in the future.

Co-authorship network of co-authors of Katia Tonkin

This figure shows the co-authorship network connecting the top 25 collaborators of Katia Tonkin. A scholar is included among the top collaborators of Katia Tonkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katia Tonkin. Katia Tonkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial 2019 ·The Lancet Oncology ·Robert E. Coleman, Dianne M. Finkelstein, Carlos H. Barrios, Miguel Martín, Hiroji Iwata, Roberto Hegg, John A. Glaspy, (unknown), Katia Tonkin, Ines Deleu, Joohyuk Sohn, John Crown, Suzette Delaloge, Tian Dai, Ying Zhou, Danielle Jandial, Arlene Chan	158
2	Feasibility Study of an Online Intervention to Support Male Spouses of Women With Breast Cancer 2017 ·Oncology nursing forum ·Wendy Duggleby, Sunita Ghosh, (unknown), Cheryl Nekolaichuk, Ceinwen E. Cumming, Roanne Thomas, Katia Tonkin, Jennifer Swindle	22
3	‘All I can do is help’: Transition experiences of male spouse caregivers of women with breast cancer 2016 ·Canadian Oncology Nursing Journal ·(unknown), Wendy Duggleby, Ceinwen E. Cumming, Roanne Thomas, Cheryl Nekolaichuk, Sunita Ghosh, Katia Tonkin	15
4	A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer 2015 ·Clinical Breast Cancer ·Michael B. Sawyer, Edith Pituskin, Sambasivarao Damaraju, Robert R. Bies, Larissa J. Vos, Carla M. Prado, Michelle Kuzma, Andrew Scarfe, Mark Clemons, Katia Tonkin, Heather‐Jane Au, Sheryl Koski, Anil A. Joy, Michael Smylie, Karen King, (unknown), Vijaya L. Damaraju, John Hanson, Carol E. Cass, John R. Mackey	17
5	Transitions of Male Partners of Women  With Breast Cancer: Hope, Guilt, and Quality of Life 2015 ·Oncology nursing forum ·Wendy Duggleby, (unknown), (unknown), Roanne Thomas, Cheryl Nekolaichuk, Sunita Ghosh, (unknown), Katia Tonkin	19
6	Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32 2015 ·JNCI Journal of the National Cancer Institute ·Pamela J. Goodwin, Wendy R. Parulekar, Karen A. Gelmon, Lois E. Shepherd, Jennifer A. Ligibel, Dawn L. Hershman, Priya Rastogi, Ingrid A. Mayer, (unknown), Julie Lemieux, Alastair M. Thompson, K.I. Pritchard, Timothy J. Whelan, Som D. Mukherjee, Haji Chalchal, Conrad D. Oja, Katia Tonkin, Vanessa Bernstein, Bingshu E. Chen, Vuk Stambolic	93
7	Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study breakdown → 2010 ·Journal of Clinical Oncology ·Alison Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard H. De Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise A. Yardley, María Eugenia Ibarrarán Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun, Ada Braun	1102
8	A Population-Based Study of the Determinants of Physical Activity in Ovarian Cancer Survivors 2009 ·Journal of Physical Activity and Health ·Clare Stevinson, Katia Tonkin, Valerie Capstick, Alexandra Schepansky, Aliya B. Ladha, Jeffrey K. Vallance, Wylam Faught, Helen Steed, Kerry S. Courneya	40
9	Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients 2009 ·Breast Cancer Research and Treatment ·Orit Freedman, Eitan Amir, George Dranitsaris, (unknown), R. Dinesh Kumar, Michael Fralick, Stephen Chia, Teresa M. Petrella, Susan Dent, Katia Tonkin, Imran Ahmad, Daniel Rayson, Mark Clemons	6
10	Correlates of exercise motivation and behavior in a population-based sample of endometrial cancer survivors: an application of the Theory of Planned Behavior 2007 ·International Journal of Behavioral Nutrition and Physical Activity ·Kristina H. Karvinen, Kerry S. Courneya, Kristin L. Campbell, R. Pearcey, G. Dundas, Valerie Capstick, Katia Tonkin	72
11	Biologic characteristics of breast cancer detected by mammography and by palpation in a screening program: a pilot study. 1997 ·PubMed ·(unknown), Katia Tonkin, (unknown), Gordon S. Doig, (unknown), F P O’Malley	10
12	Neither toxicity nor dose intensity of carboplatin is affected by glomerular filtration rate versus body surface area dose calculation in gynecologic malignancy 1994 ·International Journal of Gynecological Cancer ·Katia Tonkin, Leslie Levin, John Powe	4
13	Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone 1993 ·British Journal of Cancer ·(unknown), J. Carmichael, Katia Tonkin, (unknown), (unknown), Mitch Dowsett, Adrian L. Harris	14
14	High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines 1992 ·British Journal of Cancer ·(unknown), P. A. Philip, Adrian L. Harris, Katia Tonkin, S Houlbrook, J Kirk, (unknown), J Carmichael	54
15	HTLV-1 associated T-cell lymphoma in a patient with a 10-year history of non-epidermotropic T-cell skin infiltrates 1990 ·Clinical Oncology ·Katia Tonkin, Gordon Rustin, F.J. Paradinas	1
16	Successful treatment of patients in whom germ cell tumour masses enlarged on chemotherapy while their serum tumour markers decreased 1989 ·European Journal of Cancer and Clinical Oncology ·Katia Tonkin, G.J.S. Rustin, (unknown), F.J. Paradinas, (unknown)	38
17	A comparison of the in vivo and in vitro radiation response of three human cervix carcinomas 1989 ·Radiotherapy and Oncology ·Lloyd R. Kèlland, Katia Tonkin, G. Gordon Steel	10
18	The effect of 3-aminobenzamide in the radiation response of three human cervix carcinoma xenografts 1989 ·Radiotherapy and Oncology ·Lloyd R. Kèlland, Katia Tonkin	20
19	In vitro chemosensitivity of four new carcinoma of the cervix cell lines: Relationship to radiosensitivity 1989 ·European Journal of Cancer and Clinical Oncology ·Lloyd R. Kèlland, Katia Tonkin	9
20	Age as a confounding factor in the association of mammographic dysplasia and estrogen receptor concentration in breast cancer 1987 ·Breast Cancer Research and Treatment ·N F Boyd, E Fishell, Katia Tonkin, B.G. Mobbs	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact